Name | Bevantolol hydrochloride |
Synonyms | CI 775 Cl 775 BEVANTOLOL HCL bevantolol hydrochloride Bevantolol hydrochloride 1-[(3,4-Dimethoxyphenethyl)amino]-3-(m-tolyloxy)-2-propanol hydrochloride (±)-1-((3,4-Dimethoxyphenethyl)amino)-3-(m-tolyloxy)-2-propanol Hydrochloride 1-((2-(3,4-dimethoxyphenyl)ethyl)amino)-3-(3-methylphenoxy)-2-propanol hydrochloride 2-PROPANOL, 1-[[2-(3,4-DIMETHOXYPHENYL)ETHYL]AMINO]-3-(3-METHYLPHENOXY)-, HYDROCHLORIDE (±)-1-((2-(3,4-Dimethoxyphenyl)ethyl)amino)-3-(3-methylphenoxy)-2-propanol Hydrochloride |
CAS | 42864-78-8 |
InChI | InChI=1/C20H27NO4.ClH/c1-15-5-4-6-18(11-15)25-14-17(22)13-21-10-9-16-7-8-19(23-2)20(12-16)24-3;/h4-8,11-12,17,21-22H,9-10,13-14H2,1-3H3;1H |
Molecular Formula | C20H28ClNO4 |
Molar Mass | 381.89 |
Melting Point | 137-138° |
Boling Point | 518.3°C at 760 mmHg |
Flash Point | 267.3°C |
Solubility | DMSO (Slightly), Methanol (Slightly) |
Vapor Presure | 1.44E-11mmHg at 25°C |
Appearance | Solid |
Color | White to Off-White |
Merck | 14,1192 |
Storage Condition | Sealed in dry,Room Temperature |
Use | Content determination |
In vitro study | Bevantolol hydrochloride has a pK i of 6.23 for β2-adrenergic receptor. |
Toxicity | LD50 orl-rat: 460 mg/kg IYKEDH 26,364,1995 |
overview | bevanolol hydrochloride is a new type of selective β-receptor blocker, which is highly selective for β -1 receptor, and has mild blocking of α -1 receptor and mild calcium channel antagonism. it can block β-receptor to slow down heart rate, reduce myocardial contractility and blood pressure. Bevanolol hydrochloride (BevantololHydrochloride,NC-1400) compounds were first synthesized and discovered in 1971. The original research manufacturer was Pfizer Company of the United States, which was later researched and developed by Warner-Lambert Company of the United States. In 1987, Danish NycomedPharma Company and the Philippines applied for listing to treat hypertension and angina pectoris. In June 1995, it was produced and listed by Japan Co., Ltd. and sold in South Korea in 1998. The drug is now registered and marketed in Germany and the Netherlands. According to the existing literature, bevanolol is mainly obtained by condensation reaction of 1, 2-epoxy-3-m-methylphenoxypropanol with 3, 4-dimethoxyphenethylamine. In the literature, 1, 2-epoxy-3-m-methylphenoxypropanol is prepared by etherification of m-cresol and epichlorohydrin. However, when the temperature is higher (95 ℃), the ring-opening by-product will be mainly generated, while when the temperature is lower, although the target product is mainly obtained, the yield is lower (≤ 20%). The condensation reaction of 1,2-epoxy -3-m-methylphenoxypropanol and 3,4-dimethoxyphenylethylamine needs to be carried out at a higher temperature (90~100 ℃ or 100~110 ℃), the reaction conditions are harsh, and then ether is added to the system at room temperature to precipitate the crude bevanolol, but the ether is flammable and explosive, which is not conducive to the safety of industrial production. In addition, the refining method of bevanolol hydrochloride mentioned in the literature is mainly to recrystallize the crude product with acetonitrile and isopropanol, but acetonitrile or isopropanol has no obvious effect on the color of this product and the removal of 3,4-dimethylphenethylamine hydrochloride, and it is difficult to remove inorganic salts and is not suitable for industrial production. |
use | bevanolol hydrochloride is a new type of selective β-receptor blocker, which is highly selective for β -1 receptor, and has mild blocking α1 receptor and mild calcium channel antagonism. It can block β receptor to slow down heart rate, reduce myocardial contractility and blood pressure. |
biological activity | Bevantolol hydrochloride (NC-1400) selective β adrenergic receptor antagonist, no β endogenous sympathomimetic activity, weak membrane stability, and local anesthesia effect. |
target | pKi: 7.83 (β1-adrenergic receptor), 6.9 (α1-adrenergic receptor), 6.23 (β2-adrenergic receptor) and Ca 2 |
Animal Model: | Male Wistar rats weighing 250-300 g |
Dosage: | 200 mg/kg |
Administration: | PO by water; for 6 weeks |
Result: | Produced a significant decrease in the expression level of β1 adrenoceptor mRNA. |